STAT

APRIL 8, 2024

Anyone can now walk into a pharmacy in the United States and buy oral contraceptives over the counter without a prescription, thanks to the FDA’s approval of norgestrel (Opill). This change reflects the drug’s safety and the public health imperative to ensure wider access to birth control. But another safe class of medicine that addresses a massive public health need remains unavailable except by prescription: the antidepressants known as selective serotonin reuptake inhibitor

364

364

PharmaVoice

APRIL 8, 2024

The market is huge, but will companies overcome the triple hurdles of payer hesitance, prescriber reluctance and sluggish consumer demand?

306

306

STAT

APRIL 8, 2024

For the vast majority of pancreatic cancer cases, the tumor grows undetected until it has already spread locally or to distant parts of the body. That means most patients, over 80% by some estimates, are diagnosed when it’s already too late to do surgery — depriving them of their best chance for a cure. “For the majority of patients, we cannot resect the tumor.

363

363

PharmaVoice

APRIL 8, 2024

GenAI is profoundly reshaping various facets of the pharmaceutical industry. Projections indicate that the global GenAI market in pharma will soar to USD 2258.1 million by 2032.

264

264

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

STAT

APRIL 8, 2024

The country’s biggest hospital chain, HCA Healthcare , told the Centers for Medicare and Medicaid Services it doled out almost $1 billion more in financial assistance to needy patients than it reported on its financial statement in 2022, helping the enormously profitable company extract billions of dollars from taxpayer-funded programs. It’s normal for hospital systems to report more charity care — free and discounted care provided to low-income patients — in their an

Hospitals 362

Hospitals 362

PharmaVoice

APRIL 8, 2024

Underrepresentation of women in clinical trials affects the resulting drugs that are available down the line. Encouraging more women to partake is a critical step in promoting more equitable healthcare.

264

264

Pharma Times

APRIL 8, 2024

The project aims to advance therapeutics for tuberculosis, malaria and hepatitis C in LMICs

142

142

STAT

APRIL 8, 2024

It’s been a year since states began the process of Medicaid redetermination, going through their Medicaid rolls that had been frozen through the Covid-19 emergency period. According to data from KFF , about 21% of the people who were enrolled prior to the redetermination, or close to 20 million, lost coverage, while 45%, or 42 million, were confirmed.

334

334

BioPharma Dive

APRIL 8, 2024

Recent biotech company acquisitions have put emerging schizophrenia treatments in focus. But many development hurdles still stand in the way of new medicines for the brain.

137

137

STAT

APRIL 8, 2024

You’re reading the web version of Health Care Inc.,  STAT’s weekly newsletter  following the flow of money in medicine.  Sign up  to get it in your inbox every Monday.  The funny business of reporting charity care The concept of charity care is simple: It’s the free and discounted care that hospitals provide to low-income people.

Hospitals 299

Hospitals 299

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

Pharma Times

APRIL 8, 2024

Around three million people in the UK were estimated to be living with cancer in 2022

136

136

STAT

APRIL 8, 2024

A fully independent clinical trial researchers thought might disprove a cardiac device made by Shockwave Medical, the company that Johnson & Johnson is buying for $13 billion, ended up providing some support for the device’s utility. The data, presented Monday at the annual meeting of the American College of Cardiology and published in The Lancet , could bolster the case for the device, which is available in Europe and the U.K. but was previously rejected by the U.S.

297

297

The Pharmacist

APRIL 8, 2024

A rise in measles cases in London has brought the capital in line with the number of cases recorded in the West Midlands – the initial hotspot for the virus. This comes as the rise in cases appears to be plateauing across the country and as a national catch-up campaign has increased vaccination uptake over […] The post Measles cases in London now in line with West Midlands appeared first on The Pharmacist.

Vaccines 130

Vaccines 130

STAT

APRIL 8, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hi, it’s Meghana. Lots happened this past weekend! We have news for you from the annual meeting of the American Association for Cancer Research, and also from the annual meeting of the American College of Cardiology.

286

286

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

BioPharma Dive

APRIL 8, 2024

Underrepresentation of women in clinical trials affects the resulting drugs that become available later. Even small changes could boost participation.

119

119

STAT

APRIL 8, 2024

File this under “Not a moment too soon.” After years of back-and-forth deliberations, the U.S. Food and Drug Administration has agreed to review a rare disease drug developed by a small company that planned to shelve further work if the agency did not take this long-sought step. Specifically, the FDA accepted a new drug application from Stealth BioTherapeutics for a treatment to combat Barth syndrome, which causes an enlarged heart, muscle weakness, and a shortened life expectancy.

Drug Development 272

Drug Development 272

pharmaphorum

APRIL 8, 2024

Empower women's health with digital tools and technology. Learn about the latest advancements and resources to promote wellness and empowerment in women's health.

118

118

STAT

APRIL 8, 2024

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because the usual routine of online meetings, phone calls, and deadlines has inevitably returned. But you knew this would happen, yes? After all, what can you do? The world, such as it is, continues to spin. So in hopes of nudging it in a better direction, we are brewing cups of stimulation.

Drug Development 265

Drug Development 265

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

pharmaphorum

APRIL 8, 2024

SGLT2 inhibitors have transformed the treatment of heart failure in the last few years, but an attempt to extend their use into the setting of post-heart attack patients has suffered a setback.

118

118

Pharmaceutical Commerce

APRIL 8, 2024

In an interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld, Value & Access Advisor, Schoonveld Advisory, offers his thoughts on lower drug prices in the US and provides a sneak peak into future PC features.

Drug Pricing 105

Drug Pricing 105

pharmaphorum

APRIL 8, 2024

Stay up to date with the latest pharma and biotech hires from March 2024, including notable companies like Sitryx, Oxford, and MaaT Pharma.

115

115

Pharmaceutical Technology

APRIL 8, 2024

The FDA has approved the NDA for SH-201, an oral liquid drug that slows or stops the growth of certain types of leukaemia.

105

105

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

APRIL 8, 2024

Creating a winning playbook for consistent digital product success involves strategic planning, execution, and continuous improvement. Discover key strategies and practices to ensure your digital products achieve lasting success.

111

111

Express Pharma

APRIL 8, 2024

Generic drugs are often hailed as an effective cost-containment measure for healthcare systems that often have outdated or ineffective financing mechanisms. Despite their increasing usage, a significant proportion of healthcare professionals (HCPs) still tend to favor branded drugs, finds GlobalData. GlobalData’s survey “Generic Drugs – Physician Perspective” uncovered that if cost was not the primary factor, overall close to 40 per cent of physicians would prescribe branded drugs for thei

104

104

pharmaphorum

APRIL 8, 2024

Drugs from Ionis and Arrowhead Pharma that block apolipoprotein C-III (apoC-III) have shown their value in treating diseases associated with elevated triglyceride levels in two studies presented at the American College of Cardiology annual congress. The two companies are racing to bring their apoC-III inhibitors to market for severe hypertriglyceridaemia (HTG) and ultra-rare disorder familial chylomicronaemia syndrome (FCS).

111

111

Express Pharma

APRIL 8, 2024

Signet and BASF, in continuation of their partnership, co-organised Formulator’s Forum: Exchange on Excipients Innovation for South of India region at ITC Kakatiya, Hyderabad on March 19, 2024. The event received active participation from formulators across pharma companies in Hyderabad. The objective of this forum was to have an open discussion on current innovations in pharma formulation development especially with product offerings from BASF Pharma Solutions.

103

103

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

pharmaphorum

APRIL 8, 2024

FDA approves AstraZeneca and Daiichi Sankyo’s Enhertu for all HER2-positive solid tumours, in a first for both the HER2 inhibitor and ADC category.

111

111

Pharmaceutical Commerce

APRIL 8, 2024

The latest news for pharma industry insiders.

101

101

pharmaphorum

APRIL 8, 2024

Less than half of the cancer therapies given accelerated approval by the FDA in 2013 to 2017 showed a clinical benefit in a confirmatory trial within the next five years

110

110

Pharmaceutical Technology

APRIL 8, 2024

J&J and Legend’s CAR-T cell therapy has been approved as a second-line therapy for patients with multiple myeloma (MM).

98

98

European Pharmaceutical Review

APRIL 8, 2024

The first BCMA-targeted CAR-T cell therapy for second-line treatment of multiple myeloma has been approved by the US Food and Drug Administration (FDA). CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) is indicated for patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI), and an immunomodulatory agent (IMiD), and are refractory to lenalidomide.

Labelling 98

Labelling 98